AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program

AB Biosciences, Inc. and Shire plc (NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced that they have entered into an agreement granting Shire an exclusive worldwide license to develop and commercialize AB Biosciences’ pan receptor interacting molecule program, which uses AB Biosciences’ proprietary oligomeric Fc technology platform.
As quoted in the press release:

“This agreement provides the opportunity to accelerate the development of the PRIM program and potentially benefit patients with autoimmune and inflammatory disorders that are currently treated with the traditional human IVIg preparations,” said Yen-Ming Hsu, Ph.D., President and Chief Executive Officer of AB Biosciences, Inc.

Click here to read the full press release.